Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health concern, especially in developing countries. The challenge of antibiotic resistance and the need for effective management strategies necessitates an in-depth analysis of current approaches.
Early and accurate diagnosis is crucial in managing enteric fever. Conventional culture methods, though gold standard, are time-consuming and often yield low sensitivity. Rapid diagnostic tests, such as serological and molecular methods, offer promise for timely detection and management.
The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains poses a significant challenge. Fluoroquinolones, once first-line therapy, face increasing resistance. Third-generation cephalosporins and azithromycin are now often preferred, but vigilance for emerging resistance is necessary.
Preventive measures, such as vaccination, play a crucial role in controlling enteric fever. The WHO recommends the typhoid conjugate vaccine (TCV) for children over six months in endemic regions. Additionally, the live oral Ty21a vaccine and the Vi polysaccharide vaccine offer alternatives for specific populations.
Control measures include improving sanitation, safe drinking water supply, and food safety. Case detection and contact tracing, coupled with antimicrobial stewardship, can limit the spread of resistant strains.
Enteric fever management requires a multi-faceted approach, combining early diagnosis, effective treatment, vaccination, and stringent public health measures. The rise of antibiotic resistance underscores the importance of ongoing research into novel therapies and vaccines. As we strive for better management strategies, collaboration between clinicians, microbiologists, and public health officials is essential.
1.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
2.
Health researchers discuss Medicaid cancer screening trends, best practices
3.
Taking Charge of Your Cancer Journey.
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
3.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
4.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation